{"filing":{"accession_number":"0001615219-26-000016","cik":"0001615219","ticker":"DCOY","company_name":"Decoy Therapeutics Inc.","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-14","primary_document":"dcoy-20260914.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1615219/000161521926000016/dcoy-20260914.htm"},"events":[{"id":33686,"run_id":30986,"accession_number":"0001615219-26-000016","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This Item 5.07 discloses the results of a Special Meeting of Stockholders held on September 14, 2026, where stockholders voted on two substantive proposals: (1) approval of issuance of shares upon exercise of Series A, B, and C common warrants (81,646 votes for, 2,906 against), and (2) approval of an amendment to reduce authorized shares from 100,000,000 to 90,000,000 (234,494 votes for, 6,303 against). Both proposals passed by substantial majorities. The disclosure of shareholder vote results at a special meeting is the core purpose of Item 5.07, and the approval of warrant exercises and charter amendments are material governance and capital structure decisions.","company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":37201,"accession_number":"0001615219-26-000016","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of a Special Meeting of Stockholders held on September 14, 2026, where stockholders voted on two substantive proposals: (1) approval of issuance of shares upon exercise of Series A, B, and C common warrants (81,646 votes for, 2,906 against), and (2) approval of an amendment to reduce authorized shares from 100,000,000 to 90,000,000 (234,494 votes for, 6,303 against). Both proposals passed by substantial majorities. The disclosure of shareholder vote results at a special meeting is the core purpose of Item 5.07, and the approval of warrant exercises and charter amendments are material governance and capital structure decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T21:03:06.108051+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37201,"accession_number":"0001615219-26-000016","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of a Special Meeting of Stockholders held on September 14, 2026, where stockholders voted on two substantive proposals: (1) approval of issuance of shares upon exercise of Series A, B, and C common warrants (81,646 votes for, 2,906 against), and (2) approval of an amendment to reduce authorized shares from 100,000,000 to 90,000,000 (234,494 votes for, 6,303 against). Both proposals passed by substantial majorities. The disclosure of shareholder vote results at a special meeting is the core purpose of Item 5.07, and the approval of warrant exercises and charter amendments are material governance and capital structure decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T21:03:06.108051+00:00","company_name":"Decoy Therapeutics Inc.","ticker":"DCOY","filing_date":"2026-09-15"}]}